New York, New York--(Newsfile Corp. - August 19, 2026) - Kaplan Fox &amp; Kilsheimer LLP is investigating potential securities violations against Hims &amp; Hers Health, Inc. (&#34;Hims &amp; Hers&#34; or the

<p>New York, New York--(Newsfile Corp. - August 19, 2026) - <a href="https://api.newsfilecorp.com/redirect/WAoJKCnxkr">Kaplan Fox &#38; Kilsheimer LLP</a> is investigating potential securities violations against Hims &#38; Hers Health, Inc. ("Hims &#38; Hers" or the "Company") (NYSE:<a class="ticker" href="https://www.benzinga.com/quote/HIMS">HIMS</a>).</p><p style="text-align: center;"><a href="https://api.newsfilecorp.com/redirect/ejrOkIQPNx">CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION</a></p><p><b>If you are a Hims &#38; Hers investor and have suffered losses, or if you have information that could assist in the Hims &#38; Hers investigation, you may <a href="https://api.newsfilecorp.com/redirect/87BqntmroY">CLICK HERE</a> to contact us. You may also contact Kaplan Fox by emailing </b><a href="mailto:pmayer@kaplanfox.com"><b>pmayer@kaplanfox.com</b></a><b> or by calling (646) 315-9003.</b></p><p>On July 29, 2026, the Federal Trade Commission ("FTC"), the People of the State of California through Los Angeles County Counsel and the Utah Division of Consumer Protection sued Hims &#38; Hers in the Northern District of California. According to the FTC, the action alleges that Hims &#38; Hers fails to clearly disclose that it charges consumers for prescriptions almost immediately after they submit an intake form, despite telling consumers that they will be able to consult with a medical provider to find a treatment that is "right for them." The FTC also alleges that the company has made it difficult for consumers to cancel subscriptions and misled consumers about keeping their health information private. The FTC alleges that Hims shared consumers' health information with Meta, Snap and other third parties.</p><p>Following this news, the price of Hims &#38; Hers stock fell $4.32 per share, or 14.73%, to close at $25.00 per share on July 29, 2026.</p><p><b>WHY CONTACT KAPLAN FOX?</b></p><p>Kaplan Fox &#38; Kilsheimer LLP is a nationally recognized law firm focused on complex litigation, with offices in New York, Oakland, Los Angeles, Chicago, and New Jersey. Founded in 1956, the firm has spent more than 50 years prosecuting securities, antitrust, and consumer protection actions in federal and state courts nationwide, recovering more than $10 billion for clients and the classes it has represented.</p><p>Kaplan Fox is widely regarded as one of the nation's premier plaintiffs' securities litigation firms and has received recognition from Chambers and Partners, Benchmark Litigation, Super Lawyers, and Lawdragon. Serving as lead or co-lead counsel in many landmark cases, the firm has secured some of the largest recoveries in the history of securities litigation, including a $2.425 billion recovery on behalf of Bank of America shareholders in <i>In re Bank of America</i>&#8212;the largest recovery ever obtained for claims under Section 14(a) of the Securities Exchange Act&#8212;$800 million recovered for the Arkansas Teacher Retirement System and other pension funds in <i>ATRS v. Allianz Global Investors</i>, and a $475 million settlement in <i>In re Merrill Lynch</i>.</p><p>For decades, Kaplan Fox has represented public pension funds, institutional investors, businesses, and individuals in high-stakes litigation. Through its successful advocacy and precedent-setting victories, the firm has helped shape important areas of securities and corporate law while advancing accountability and protecting investor interests.</p><p>This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. Past results do not guarantee future outcomes.</p><p>If you have any questions about this investigation, please contact:</p><div id="contactInfo"><p><b>CONTACT:</b><br />Pamela A. Mayer<br /><a href="https://api.newsfilecorp.com/redirect/KLzRoU3mZv">KAPLAN FOX &#38; KILSHEIMER LLP</a><br />800 Third Avenue, 38th Floor<br />New York, New York 10022<br />(646) 315-9003<br /><a href="mailto:pmayer@kaplanfox.com">pmayer@kaplanfox.com</a></p><p>Laurence D. King<br /><a href="https://api.newsfilecorp.com/redirect/EZq8QTvQR0">KAPLAN FOX &#38; KILSHEIMER LLP</a><br />1999 Harrison Street, Suite 1501<br />Oakland, California 94612<br />(415) 772-4704<br /><a href="mailto:lking@kaplanfox.com">lking@kaplanfox.com</a></p></div><p>Contacting or submitting information to Kaplan Fox &#38; Kilsheimer LLP does not create an attorney-client relationship, nor an obligation on the part of Kaplan Fox to retain you as a client.</p><p><a href="https://api.newsfilecorp.com/redirect/xEpMDuVWro">https://www.kaplanfox.com/case/hims-hers-health-inc-class-action-investigation-learn-more-now/</a></p><p id="corporateNewsLogoContainer"><img src="https://images.newsfilecorp.com/files/12532/310142_21de9e6634b73aa7_logo.jpg" id="corporateNewsLogo" alt="Corporate Logo" /></p><p id="corporateLinkBack">To view the source version of this press release, please visit <a href="https://api.newsfilecorp.com/redirect/7nkEqtPoDZ">https://www.newsfilecorp.com/release/310142</a></p><p><img src="https://api.newsfilecorp.com/newsinfo/310142/197" alt="" /></p>

HIMS

Kaplan Fox is Investigating Hims & Hers Health, Inc. (HIMS) on Behalf of Investors for Potential Securities Law Violations

FTC Lawsuit Against Hims & Hers Triggers Near-Term Regulatory Risk, Shares Slide

Hims & Hers Health Inc. (NYSE:HIMS) CEO Andrew Dudum defended the telehealth company as it navigates...

Hims & Hers Rejects Privacy Allegations While Promising Expanded Patient Access

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>New York, New York--(Newsfile Corp. - August 19, 2026) - Kaplan Fox &amp;amp; Kilsheimer LLP is investigating potential securities violations against Hims &amp;amp; Hers Health, Inc. (&amp;#34;Hims &amp;amp; Hers&amp;#34; or the</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Regulators allege Hims &amp; Hers misled customers about prescription charges and privacy, and the company allegedly shared health data with third parties. The July 29 FTC suit, followed by a 14.7% share drop to $25, heightens regulatory and litigation risk. The case could pressure margins and customer retention, with potential settlements shaping the stock&#039;s near-term trajectory.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>FTC, California, and Utah sue Hims &amp; Hers; alleges improper disclosures and privacy issues.</li><li>Hims stock fell 14.73% to $25.00 on July 29, 2026.</li><li>Kaplan Fox &amp; Kilsheimer LLP launches securities investigation into Hims &amp; Hers.</li><li>FTC alleges immediate prescription charges, cancelation barriers, and data sharing with Meta/Snap.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Hims &amp; Hers Health, Inc. (HIMS)</strong>: Facing FTC/state actions alleging improper disclosures and privacy issues; regulatory risk could weigh on valuation.</li><li><strong>Meta Platforms, Inc. (META)</strong>: Named as a data-sharing partner; privacy scrutiny could affect collaboration terms.</li><li><strong>Snap Inc. (SNAP)</strong>: Alleged data-sharing with third parties; similar regulatory exposure.</li><li><strong>Kaplan Fox &amp; Kilsheimer LLP (N/A)</strong>: Leading plaintiffs&#039; firm; indicates ongoing securities litigation environment around HIMS.</li></ul>
  </section>

  <section data-block="category">
    <h3>Legal</h3>
    <p>Legal category: Active government action plus private litigation inquiry; implications for regulatory risk, potential penalties, and investor sentiment.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Regulatory actions against Hims &amp; Hers heighten near-term downside risk and investor uncertainty.</li><li>July 29, 2026 stock drop underscores immediate market reaction.</li><li>Possible fines and settlement costs could pressure margins and subscriber retention.</li><li>Data privacy scrutiny could affect partnerships and user-trust milestones.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Date: July 29, 2026 — FTC, California AG, and Utah Division sued Hims &amp; Hers in Northern District of California.</li><li>Stock closed at $25.00, down $4.32 (-14.73%) on July 29, 2026.</li><li>FTC alleges immediate prescription charging after intake and misleading privacy assurances.</li><li>FTC alleges difficulties canceling subscriptions and sharing health information with Meta and Snap.</li><li>Kaplan Fox &amp; Kilsheimer LLP announced securities investigation into Hims &amp; Hers.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Bearish near-term on regulatory risk; monitor for settlement or clarity within 1–3 quarters.</p>
  </section>
</section>


<p>New York, New York--(Newsfile Corp. - August 19, 2026) - <a href="https://api.newsfilecorp.com/redirect/WAoJKCnxkr">Kaplan Fox &#38; Kilsheimer LLP</a> is investigating potential securities violations against Hims &#38; Hers Health, Inc. ("Hims &#38; Hers" or the "Company") (NYSE:<a class="ticker" href="https://www.benzinga.com/quote/HIMS">HIMS</a>).</p><p style="text-align: center;"><a href="https://api.newsfilecorp.com/redirect/ejrOkIQPNx">CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION</a></p><p><b>If you are a Hims &#38; Hers investor and have suffered losses, or if you have information that could assist in the Hims &#38; Hers investigation, you may <a href="https://api.newsfilecorp.com/redirect/87BqntmroY">CLICK HERE</a> to contact us. You may also contact Kaplan Fox by emailing </b><a href="mailto:pmayer@kaplanfox.com"><b>pmayer@kaplanfox.com</b></a><b> or by calling (646) 315-9003.</b></p><p>On July 29, 2026, the Federal Trade Commission ("FTC"), the People of the State of California through Los Angeles County Counsel and the Utah Division of Consumer Protection sued Hims &#38; Hers in the Northern District of California. According to the FTC, the action alleges that Hims &#38; Hers fails to clearly disclose that it charges consumers for prescriptions almost immediately after they submit an intake form, despite telling consumers that they will be able to consult with a medical provider to find a treatment that is "right for them." The FTC also alleges that the company has made it difficult for consumers to cancel subscriptions and misled consumers about keeping their health information private. The FTC alleges that Hims shared consumers' health information with Meta, Snap and other third parties.</p><p>Following this news, the price of Hims &#38; Hers stock fell $4.32 per share, or 14.73%, to close at $25.00 per share on July 29, 2026.</p><p><b>WHY CONTACT KAPLAN FOX?</b></p><p>Kaplan Fox &#38; Kilsheimer LLP is a nationally recognized law firm focused on complex litigation, with offices in New York, Oakland, Los Angeles, Chicago, and New Jersey. Founded in 1956, the firm has spent more than 50 years prosecuting securities, antitrust, and consumer protection actions in federal and state courts nationwide, recovering more than $10 billion for clients and the classes it has represented.</p><p>Kaplan Fox is widely regarded as one of the nation's premier plaintiffs' securities litigation firms and has received recognition from Chambers and Partners, Benchmark Litigation, Super Lawyers, and Lawdragon. Serving as lead or co-lead counsel in many landmark cases, the firm has secured some of the largest recoveries in the history of securities litigation, including a $2.425 billion recovery on behalf of Bank of America shareholders in <i>In re Bank of America</i>&#8212;the largest recovery ever obtained for claims under Section 14(a) of the Securities Exchange Act&#8212;$800 million recovered for the Arkansas Teacher Retirement System and other pension funds in <i>ATRS v. Allianz Global Investors</i>, and a $475 million settlement in <i>In re Merrill Lynch</i>.</p><p>For decades, Kaplan Fox has represented public pension funds, institutional investors, businesses, and individuals in high-stakes litigation. Through its successful advocacy and precedent-setting victories, the firm has helped shape important areas of securities and corporate law while advancing accountability and protecting investor interests.</p><p>This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. Past results do not guarantee future outcomes.</p><p>If you have any questions about this investigation, please contact:</p><div id="contactInfo"><p><b>CONTACT:</b><br />Pamela A. Mayer<br /><a href="https://api.newsfilecorp.com/redirect/KLzRoU3mZv">KAPLAN FOX &#38; KILSHEIMER LLP</a><br />800 Third Avenue, 38th Floor<br />New York, New York 10022<br />(646) 315-9003<br /><a href="mailto:pmayer@kaplanfox.com">pmayer@kaplanfox.com</a></p><p>Laurence D. King<br /><a href="https://api.newsfilecorp.com/redirect/EZq8QTvQR0">KAPLAN FOX &#38; KILSHEIMER LLP</a><br />1999 Harrison Street, Suite 1501<br />Oakland, California 94612<br />(415) 772-4704<br /><a href="mailto:lking@kaplanfox.com">lking@kaplanfox.com</a></p></div><p>Contacting or submitting information to Kaplan Fox &#38; Kilsheimer LLP does not create an attorney-client relationship, nor an obligation on the part of Kaplan Fox to retain you as a client.</p><p><a href="https://api.newsfilecorp.com/redirect/xEpMDuVWro">https://www.kaplanfox.com/case/hims-hers-health-inc-class-action-investigation-learn-more-now/</a></p><p id="corporateNewsLogoContainer"><img src="https://images.newsfilecorp.com/files/12532/310142_21de9e6634b73aa7_logo.jpg" id="corporateNewsLogo" alt="Corporate Logo" /></p><p id="corporateLinkBack">To view the source version of this press release, please visit <a href="https://api.newsfilecorp.com/redirect/7nkEqtPoDZ">https://www.newsfilecorp.com/release/310142</a></p><p><img src="https://api.newsfilecorp.com/newsinfo/310142/197" alt="" /></p>

Regulators allege Hims & Hers misled customers about prescription charges and privacy, and the company allegedly shared health data with third parties. The July 29 FTC suit, followed by a 14.7% share drop to $25, heightens regulatory and litigation risk. The case could pressure margins and customer retention, with potential settlements shaping the stock's near-term trajectory.

News insight

Kaplan Fox is Investigating Hims & Hers Health, Inc. (HIMS) on Behalf of Investors for Potential Securities Law Violations

AI summary

Sentiment rationale

Key facts

Legal